Business Wire

TX-FLUENCE

Share
Fluence Broad Spectrum LED Lighting Selected for New High-Tech Quarantine Greenhouse in the Netherlands

Fluence by OSRAM (Fluence) has been selected by Wageningen University & Research (WUR) as the lighting provider for Serre Red, the university’s new, high-tech quarantine greenhouse. Serre Red will be used for critical research on plant diseases—caused by viruses, bacteria, fungi and parasitic nematodes—including quarantine pathogens, as well as research on genetically modified organisms.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200526005096/en/

Built by Bosman van Zaal, Serre Red is one of the most advanced quarantine research facilities constructed to date. It features 63 compartments, ranging from 15 to 52 square meters with individual climate control, air filtering and access locks. Extensive technical equipment has been installed in a corridor sunk below ground level to avoid excess shade. Other features of the fully electric greenhouse include insulated double glazing, external shading, heat/cold storage and autoclaving, which sterilizes all materials including water and waste before leaving the greenhouse.

Broad spectrum lighting: Choosing LED over HPS

To reduce the influence of artificial light on their experiments, WUR’s researchers required broad spectrum lighting. Unifarm, the university’s greenhouse and field research facility, ran a market consultation during November and December 2019, then selected four manufacturers from a tender in January 2020. Fluence was granted the order in April after the four potential solutions were examined by WUR’s scientific committee.

“Traditionally, our greenhouses are equipped with HPS lighting,” said Dolf Straathof, head of Unifarm. “As we want to eliminate any influences that artificial lighting could have on experiments, we looked for a solution that came closest to the spectrum that our scientific team specified as optimal.”

“Fluence was one of those consulted, and they proposed higher light levels than we initially specified, which concurred with recommendations from our researchers,” Straathof continued. “The PhysioSpec® solution that Fluence proposed also fit our spectral requirements. In the end, Fluence offered us the best possible solution and exceeded our requirements for uniformity, offering the highest uniformity for a mix of low and tall crops throughout all compartments.”

Optimizing light levels and uniformity

Each compartment will have individual lighting controls, linked to the Hoogendoorn climate control system.

“This is the first time WUR has chosen LED, and specifically broad spectrum LED, as their standard lighting solution for a research greenhouse at Unifarm,” said Theo Tekstra, Fluence’s technical director in Europe, the Middle East and Africa and lead for the project’s design and implementation. “LED solutions have the added advantage that they can be controlled without change in spectrum or loss of efficiency, offering constant light levels and optimal daily light integral. By using our compact VYPR 2x2 full spectrum LED fixtures with the new compact PSU drivers and VYPR reflectors, we minimize shading and optimize overall uniformity. We are extremely proud that our solution was selected as the best in the tender and that we were awarded the contract for this prestigious project.”

Critical research for the world’s growers

Fluence supports, sponsors and collaborates on horticultural research projects throughout the world, including its membership in the Wageningen Research Club of 100—part of the WUR Business Unit for Greenhouse Horticulture in Bleiswijk.

The spread of viral infections—such as the tomato brown rugose fruit virus (ToBRFV)—remains a top concern for growers throughout the world. The new Serre Red facility enables WUR to expand and intensify its research capabilities, maintaining its position as a world leader in research on horticultural crop pathogens.

“ToBRFV currently threatens tomato, bell pepper and chili pepper crops throughout the globe, causing most production greenhouses to close to visitors and creating increased costs for growers through extensive disinfection and other precautionary measures,” said Dr. Theoharis Ouzounis, horticultural scientist at Fluence. “There is no treatment other than prevention and pervasive damage has been reported globally. Research into prevention and treatment of viral diseases is extremely important to safeguard our food production.”

For more information about Fluence lighting solutions, visit www.fluence.science .

About Fluence by OSRAM

Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM , creates the most powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, The Netherlands. For more information about Fluence, visit www.fluence.science .

Link to high resolution pictures: www.fluence.science/press-links

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ViaLase Announces First Patient Treated in IDE Clinical Trial Evaluating Its Femtosecond Laser Trabeculotomy for Open-Angle Glaucoma3.12.2025 14:00:00 CET | Press release

Prospective, randomized controlled trial compares novel femtosecond laser procedure to selective laser trabeculoplasty (SLT), advancing path to US commercialization ViaLase, Inc., a clinical-stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced that the first patient has been treated in its U.S. Investigational Device Exemption (IDE) clinical trial evaluating the company’s femtosecond laser trabeculotomy procedure for the management of glaucoma, a lifelong, progressive, and incurable disease that remains a leading cause of irreversible blindness worldwide. This prospective, multicenter, randomized, controlled trial evaluates the ViaLase procedure in comparison to selective laser trabeculoplasty (SLT), the current standard laser treatment for reducing intraocular pressure (IOP). This trial was designed in consultation with the FDA to achieve clearance and commercialization in the U.S. and thus represents one of the most rigorous e

Winchester Interconnect Launches LiteSPEed™ Cable: Faster, Lighter, Simpler Connectivity for Mission-Critical Systems3.12.2025 14:00:00 CET | Press release

Winchester Interconnect, an Aptiv company and leading supplier of high-performance interconnect solutions, today introduced LiteSPEed™ Cable, a next-generation single-pair Ethernet (SPE) solution that delivers 10-gigabit data rates in a dramatically smaller, lighter design. Built for the increasingly connected and space-constrained environments of aerospace, defense, industrial automation and next-generation mobility, LiteSPEed™ helps customers move more data with less cable, reducing weight, complexity, and cost while increasing system performance and reliability. “As systems become more intelligent and interconnected, engineers need lighter, more efficient ways to deliver power and data,” said Juan Contreres, director of product management. “LiteSPEed™ gives them a rugged, high-speed Ethernet solution that simplifies installation without compromising performance.” With advanced sensors, real-time analytics, and distributed control systems proliferating across industries, cabling has

Owkin Announces International Validation Results of BRCAura: AI-Driven Screening for gBRCA Mutations Directly From Pathology Slides3.12.2025 14:00:00 CET | Press release

Owkin shares promising validation results for BRCAura RUO, a clinical-grade research-use-only AI product designed to screen for germline BRCA1/2 mutations (gBRCAm) directly from digitized breast cancer pathology slides. Breast cancer remains the leading cause of cancer-related deaths among women worldwide. Identifying patients with germline BRCA1/2 mutations is essential for guiding targeted treatment decisions, but testing is not always consistently offered to eligible individuals, and implementation varies between countries. The model concept was initiated as part of Owkin’s ongoing partnership with Gustave Roussy and Centre Léon Bérard through PortrAIt, a French consortium dedicated to advancing precision medicine with AI-enabled digital pathology. Fostered through collaboration with AstraZeneca, as announced in October 2024, the development of BRCAura aims to accelerate and expand identification of BRCA mutations in patients with breast cancer. Strong validation across internationa

Adva Network Security achieves BSI approval for PQC-encrypted edge networking device3.12.2025 14:00:00 CET | Press release

News summary: Critical infrastructure, defense and governments need quantum-safe encryption at the edge to neutralize ‘harvest-now, decrypt-later’ risks FSP 150-XG118Pro (CSH) delivers quantum-safe encryption via software update, enabling seamless upgrades with no hardware changes BSI approval confirms the device’s compliance for government and defense use Adva Network Security today announced that the FSP 150-XG118Pro (CSH) 10Gbit/s edge device now delivers quantum-safe encryption based on post-quantum cryptography (PQC). This enhancement enables operators of critical network infrastructure (CNI) to secure data in motion and build future-ready networks. Certified by the German Federal Office for Information Security (BSI), the solution’s Ethernet encryption offers PQC crypto-agility via a software update, eliminating the need for hardware changes. With its new capabilities, the FSP 150-XG118Pro (CSH) is ideally suited for diverse high-security environments, ranging from national infra

Meiji Seika Pharma Invests in Lyric Bio for Next-Generation Human Immunoglobulin Manufacturing3.12.2025 14:00:00 CET | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President: Toshiaki Nagasato) today announced a strategic equity investment in Lyric Bio, Inc. (Head Office: San Carlos, USA, founded by Chief Executive Officer: Kayj Shannon and Chief Scientific Officer Melanie Matheu). Through this investment, Meiji Seika Pharma seeks to accelerate the early-stage development of Lyric Bio’s innovative platform for producing human immunoglobulin (IVIg), explore donation-independent manufacturing methods, and lay the groundwork for a more resilient, high-quality supply of plasma-derived therapeutics to meet increasing global demand. Lyric Bio is developing a next-generation biomanufacturing platform for IVIg production. The company’s approach uses tissue-mimicking bioreactors built on a proprietary laser-printed cellular substrate that enables ultra high-density cell growth and has the potential to deliver more than 1,000 IVIg doses from a single donor. This investment will accelerate Lyric Bio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye